Inventiva S.A. American Depository Shares
Symbol: IVA (NASDAQ)
Company Description:
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
- Today's Open: $5.53
- Today's High: $5.835
- Today's Low: $5.4
- Today's Volume: 18.08K
- Yesterday Close: $5.52
- Yesterday High: $6.01
- Yesterday Low: $5.51
- Yesterday Volume: 101.01K
- Last Min Volume: 300
- Last Min High: $5.4
- Last Min Low: $5.4
- Last Min VWAP: $5.4
- Name: Inventiva S.A. American Depository Shares
- Website: https://www.inventivapharma.com
- Listed Date: 2020-07-10
- Location: ,
- Market Status: Active
- CIK Number: 0001756594
- SIC Code:
- SIC description:
- Market Cap: $767.61M
- Round Lot: 100
- Outstanding Shares: 139.06M
- Asset Type: ADRC
Filing Date | Filing Type | Format |
---|---|---|
2025-10-01 | 6-K | View |
2025-09-29 | 6-K | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-07-31 | SCHEDULE 13G/A | View |
2025-07-29 | 6-K | View |
2025-07-09 | 6-K | View |
2025-07-07 | 6-K | View |
2025-06-20 | SCHEDULE 13G | View |
2025-05-23 | 6-K | View |
2025-05-23 | 6-K | View |
2025-05-22 | 6-K | View |
2025-05-15 | SCHEDULE 13G | View |
2025-05-09 | SCHEDULE 13D/A | View |
2025-05-07 | SCHEDULE 13D/A | View |
2025-05-05 | 6-K | View |
2025-05-02 | 6-K | View |
2025-04-30 | 6-K | View |
2025-04-30 | 6-K | View |
2025-04-24 | 6-K | View |
2025-04-15 | 20-F | View |